You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

295 Results
Document
Nov 2022
Document
Dec 2022
Document
Dec 2022
Document
Dec 2022
Document
Mar 2023
Statistical Reports
Apr 2023
Document
Jun 2023
Drug
Other Name(s): Trodelvy®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jul 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Hairy Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
vemURAFenib (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2023
Regimen
Cancer Type:
Endocrine, 
Thyroid
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    selpercatinib - For the treatments of advanced or metastatic RET fusion-positive differentiated thyroid carcinoma (DTC); and unresectable advanced or metastatic RET-mutant medullary thyroid cancer (MTC)
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
selpercatinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2025

Pages